Bacillus amyloliquefaciens TL106 protects mice against enterohaemorrhagic Escherichia coli O157:H7-induced intestinal disease through improving immune response, intestinal barrier function and gut microbiota.
C L BaoS Z LiuZ D ShangY J LiuJ WangW X ZhangB DongYunhe CaoPublished in: Journal of applied microbiology (2020)
Bacillus amyloliquefaciens TL106 can prevent and treat intestinal disease induced by EHEC O157:H7 in mice, which may be a promising probiotic for disease prevention in animals.